DIRS.INFO The most relevant business & tech news

FRANKFURT, July 29 (Reuters) - Novo Nordisk has launched blockbuster weight-loss drug Wegovy in Germany, its first big European market, hoping Germans will pay hundreds of euros out of pocket for a drug that public health insurance plans are so far barred from covering. The Danish drugmaker's share price has more than doubled in the two years since the drug debuted, turning Novo (NOVOb.CO) into Europe's second-most-valuable listed company after LVMH. Among major providers, Allianz (ALVG.DE) says it will pay if a physician diagnoses a medical need, while Debeka said its plans exclude weight-loss treatments. Novo is ramping up production to meet soaring demand in the United States, where the drug sells for as much as $1,350 a month. Doctors say many Germans seeking to lose weight have already used Ozempic, a diabetes drug also made by Novo that is a lower dose version of the same ingredient as Wegovy.

Persons: Wegovy, Debeka, Robert Koch, Ludwig Burger, Maggie Fick Organizations: Novo Nordisk, Novo, LVMH, Allianz, European Union, Robert Koch Institute, Thomson Locations: FRANKFURT, Germany, United States, Europe, Norway, Denmark, Danish, Novo, Wegovy, Frankfurt, London

Interviews with seven doctors and two other potential users of Wegovy from Germany, where Novo Nordisk's (NOVOb.CO) weight-loss drug will become available at the end of July, show the office administrator isn't alone. Allianz (ALVG.DE) says it will pay if a physician diagnoses a medical need while Debeka said its plans exclude weight-loss treatments. In Germany, Wegovy will be administered with the same injection pen used in Norway and Denmark, not the one used in the United States to avoid hitting supplies there. "Patients are so desperate in Germany that they will pay out of their pocket for the medication." "My experience is that people will be able to pay for it out of (their own) pocket," said Horbach.

Persons: Doctor Thomas Horbach, Wegovy, Novo, Jessica Lenth, isn't, I've, Lenth, Debeka, Robert Koch, Danish drugmaker, Sylvia Weiner, Karl Rheinwalt, Thomas Horbach, Weiner, Rheinwalt, Juergen Ordemann, Michael Wirtz, Wirtz, Irina Ernstberger, Ernstberger, Ludwig Burger, Maggie Fick, Patricia Weiss, Josephine Mason, Catherine Evans Organizations: Novo Nordisk, FRANKFURT, Reuters, Allianz, European Union, Robert Koch Institute, Sana Klinikum, St, Hospital, Ozempic, Novo, Thomson Locations: Germany, Munich, LONDON, Hamburg, Wegovy, United States, Danish, Norway, Denmark, Sana, Frankfurt, St Franziskus, Hospital Cologne, Berlin's, Winsen, Lower Saxony, London

☆ German panel recommends COVID shot only for at-risk youngsters
▼ + stars: | 2022-11-17 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

The recommendation also covers a version of Moderna's (MRNA.O) Spikevax vaccine for the age group but that product is in short supply in Germany at the moment, the expert panel said. European regulators in October authorised a low-dose version of Pfizer-BioNTech's first-generation vaccine for children from six months to four years, when given as a three-dose series. "When there are parents that absolutely want the vaccine for their healthy children, there are no legal reason for physicians to deny them that," said STIKO's Terhardt. STIKO also reaffirmed a recommendation it issued in May for five- to 11-year-olds, saying one COVID-19 shot was enough for healthy youngsters in that age group because most of them had already had an infection. Only slightly more than 22% of five- to 11-year-old children in Germany have so far received at least one COVID shot.

☆ Fact Check-Germany has not halted administration of all COVID-19 vaccines
▼ + stars: | 2022-09-15 | by ( Reuters Fact Check | ) www.reuters.com time to read: +5 min

Germany has dismissed resurfaced claims on social media that it has halted administration of all COVID-19 vaccines. A spokesperson for the German Federal Ministry of Health (Bundesministerium für Gesundheit) confirmed to Reuters that no such ban has been made. “I can confirm that Germany has not banned or paused the COVID-19 vaccinations in Germany,” a spokesperson for the German Federal Ministry of Health told Reuters. The list of authorized COVID-19 vaccines per the German Federal Institute for Vaccines and Biomedicines can be found (here). Germany has not halted administration of COVID-19 vaccines.

☆ Anunțul făcut de Germania privind vaccinarea cu AstraZeneca
▼ + stars: | 2021-05-07 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +2 min

Miniştrii Sănătăţii din cele 16 landuri germane s-au pus de acord cu ministrul Spahn pentru a anula o decizie precedentă, care restricţiona vaccinul AstraZeneca şi îl autoriza doar pentru persoanele de peste 60 de ani. Jens Spahn a mai spus totodată că actualul interval de 12 săptămâni între prima şi a doua doză a vaccinului AstraZeneca ar putea fi scurtat. Zeci de ţări au suspendat utilizarea vaccinului AstraZeneca în luna martie sau l-au restricţionat autorizându-l doar pentru adulţii vârstnici după raportarea unor evenimente trombotice foarte rare, dar grave. Jens Spahn a mai spus totodată că Germania intenţionează să ofere vaccinuri anti-COVID-19 adolescenţilor între 12 şi 18 ani până la sfârşitul lunii august, dacă Agenţia Europeană pentru Medicamente (EMA) va autoriza vaccinul Pfizer-BioNTech pentru această grupă de vârstă. Germania va relaxa restricţiile începând din acest weekend pentru persoanele vaccinate cu ambele doze sau care s-au recuperat după ce au contractat maladia COVID-19.

Persons: Jens Spahn, Reuters, Robert Koch Organizations: Robert Koch Institute Locations: Germania, Agerpres, Germaniei

Search resuls for: "Robert Koch Institute"

5 mentions found